NCT00004022View on ClinicalTrials.gov

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 1997

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

autologous tumor cell vaccine

BIOLOGICAL

muromonab-CD3

BIOLOGICAL

therapeutic autologous lymphocytes

PROCEDURE

surgical procedure

Trial Locations (1)

48201

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER

NCT00004022 - Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter